AtriCure, Inc. to Post Q1 2021 Earnings of ($0.16) Per Share, Oppenheimer Forecasts (NASDAQ:ATRC)


Share on StockTwits

AtriCure, Inc. (NASDAQ:ATRC) – Investment analysts at Oppenheimer lifted their Q1 2021 earnings estimates for shares of AtriCure in a research report issued on Monday, January 11th. Oppenheimer analyst S. Kalia now forecasts that the medical device company will post earnings per share of ($0.16) for the quarter, up from their previous forecast of ($0.20). Oppenheimer also issued estimates for AtriCure’s Q2 2021 earnings at ($0.16) EPS, Q4 2021 earnings at ($0.14) EPS and FY2021 earnings at ($0.59) EPS.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Tuesday, November 10th. The medical device company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.23. The business had revenue of $54.80 million during the quarter, compared to analysts’ expectations of $49.37 million. AtriCure had a negative return on equity of 14.83% and a negative net margin of 21.74%. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.33) EPS.

Several other equities analysts also recently weighed in on ATRC. Needham & Company LLC raised their price target on AtriCure from $53.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, December 18th. Zacks Investment Research downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday, January 5th. BidaskClub cut AtriCure from a “buy” rating to a “hold” rating in a research note on Thursday, December 31st. ValuEngine cut shares of AtriCure from a “buy” rating to a “hold” rating in a research note on Tuesday, January 5th. Finally, SVB Leerink lifted their price objective on shares of AtriCure from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Monday, December 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $54.63.

Shares of ATRC stock opened at $58.69 on Thursday. The stock has a fifty day moving average price of $51.58 and a 200 day moving average price of $43.82. The stock has a market cap of $2.64 billion, a PE ratio of -51.03 and a beta of 1.13. AtriCure has a 1 year low of $23.17 and a 1 year high of $59.80. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.85 and a current ratio of 6.62.

In other AtriCure news, CEO Michael H. Carrel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $59.00, for a total value of $1,475,000.00. Following the transaction, the chief executive officer now directly owns 529,795 shares of the company’s stock, valued at $31,257,905. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael H. Carrel sold 75,000 shares of the stock in a transaction that occurred on Thursday, December 17th. The stock was sold at an average price of $51.00, for a total value of $3,825,000.00. Following the transaction, the chief executive officer now owns 529,504 shares in the company, valued at $27,004,704. The disclosure for this sale can be found here. Over the last quarter, insiders sold 184,514 shares of company stock worth $9,830,096. Company insiders own 5.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc boosted its position in AtriCure by 42.2% during the 3rd quarter. IFP Advisors Inc now owns 1,035 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 307 shares during the period. Nisa Investment Advisors LLC acquired a new stake in AtriCure in the 3rd quarter valued at $48,000. HighMark Wealth Management LLC increased its stake in AtriCure by 1,285.9% in the 3rd quarter. HighMark Wealth Management LLC now owns 2,841 shares of the medical device company’s stock valued at $78,000 after buying an additional 2,636 shares during the last quarter. Great West Life Assurance Co. Can increased its stake in shares of AtriCure by 35.4% during the 2nd quarter. Great West Life Assurance Co. Can now owns 3,162 shares of the medical device company’s stock worth $141,000 after purchasing an additional 827 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of AtriCure by 9.7% in the 3rd quarter. US Bancorp DE now owns 3,257 shares of the medical device company’s stock valued at $130,000 after purchasing an additional 287 shares during the period. 94.70% of the stock is owned by institutional investors.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

See Also: FAANG Stocks

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.